REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1647401
This article is part of the Research TopicMechanisms and Complexities Underlying the Cancer Cell Immune Evasion and its Therapeutic ImplicationsView all 7 articles
Advances in the Study of TIM3 in Myelodysplastic Syndrome
Provisionally accepted
- 1Tianjin Medical University General Hospital, Tianjin, China
- 2Peking University People's Hospital, Beijing, China
- 3Center for Molecular Medicine, University of Georgia. 325 Riverbend Road, Athens, GA, 30602., Athens, GA, American Samoa
- 4The Affiliated Hospital of Qingdao University, Qingdao, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Myelodysplastic syndromes (MDS) are heterogeneous myeloid clonal disorders derived from hematopoietic stem cells. The incidence of MDS (1.51/100,000 in China, 4-5/100,000 in Europe and America) is higher than any subtype of leukemia. In recent years, the imbalance of immune regulation and tumor microenvironmental disorders have received increasing attention in the pathogenesis of MDS. T-cell immunoglobulin and mucin-domain containing protein 3 (TIM-3) is an important inhibitory immune checkpoint molecule, widely expressed in T cells, NK cells, and dendritic cells, monocytes/macrophages and other immune cells.Numerous studies have confirmed that TIM-3 is aberrantly expressed in a variety of solid and hematologic tumors and plays an important role in regulating tumor escape and immune depletion. In this paper, we focus on reviewing the relevant studies of TIM-3 in MDS and summarize the findings of our team in this field. We also discuss the potential application of TIM-3 in the diagnosis and treatment of MDS in conjunction with the latest clinical trials. Blocking TIM-3 has both 'tumor cell-targeted inhibition' and 'immune function remodeling' dual roles in MDS disease progression, which provides new therapeutic strategies and hope for MDS patients.
Keywords: T-cell Immunoglobulin Mucin 3 (TIM-3), myelodysplastic syndrome (MDS), immune checkpoints, immune escape, targeted therapy
Received: 15 Jun 2025; Accepted: 23 Jul 2025.
Copyright: © 2025 Li, Guo, Yu, Tao, Wang, Shao and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lijuan Li, Tianjin Medical University General Hospital, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.